Teva Pharmaceutical Industries Limited (TEVA)
| Previous close | 7.95 |
| Open | 7.80 |
| Bid | 7.59 x 4000 |
| Ask | 7.60 x 900 |
| Day's range | 7.57 - 7.82 |
| 52-week range | 7.23 - 10.50 |
| Volume | |
| Avg. volume | 9,903,732 |
| Market cap | 8.361B |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | 11.48 |
| EPS (TTM) | 0.66 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 27 Nov 2017 |
| 1y target est | 11.36 |
- Business Wire
Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022
TEL AVIV, Israel, June 29, 2022--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2022 financial results on Wednesday, July 27, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
- Motley Fool
2 Buffett Stocks That Outperformed the S&P During the Great Recession
There are two things that Teva Pharmaceutical Industries (NYSE: TEVA) and Amazon (NASDAQ: AMZN) have in common. While the index fell by 38% during that time, the healthcare company climbed 10% in value, and the tech giant's 8% decline was modest by comparison. Teva provides patients with generic medications that are much cheaper than brand-name drugs.
- Simply Wall St.
Teva Pharmaceutical Industries (NYSE:TEVA) investors are sitting on a loss of 76% if they invested five years ago
We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...
